{"id":"W3168935284","doi":"10.1038/s41586-021-03642-9","title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","year":2021,"lang":"en","type":"article","venue":"Nature","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":604,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Hazard ratio; Medicine; Atezolizumab; Internal medicine; Confidence interval; Oncology; Population; Clinical endpoint; Adjuvant; Bladder cancer; Adjuvant therapy; Biomarker; Immunotherapy; Cancer; Randomized controlled trial; Nivolumab; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006553739,0.0001390623,0.0002569826,0.00007049734,0.00003786571,0.00001487856,0.00006500214,0.000560376,0.0005851037],"category_scores_gemma":[0.00004121911,0.0001157001,0.0001010695,0.0002519818,0.00001820779,0.00004574938,0.00002156245,0.0007819328,0.00003597622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000131739,"about_ca_system_score_gemma":0.0002922631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008153452,"about_ca_topic_score_gemma":0.00004775873,"domain_scores_codex":[0.9990857,0.00003393913,0.0001610465,0.0002635789,0.0002280041,0.0002277508],"domain_scores_gemma":[0.9995224,0.00002083731,0.0000261092,0.0002850419,0.00007944242,0.00006609802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001859818,0.001055275,0.5510423,0.000178326,0.0003640082,0.00556065,0.002337756,0.000005088396,0.3210591,0.001623182,0.01573646,0.09917798],"study_design_scores_gemma":[0.01254966,0.0003344485,0.6325203,0.0002443051,0.00009077544,0.0004449544,0.0002873371,0.00003940212,0.2020785,0.0005687483,0.1505137,0.0003278838],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9426072,0.02755944,0.00001443237,0.003808284,0.0007409886,0.000307441,0.00003234047,0.00005674054,0.02487308],"genre_scores_gemma":[0.9912376,0.0002936136,0.0004526228,0.004802508,0.0003489322,0.00001873963,0.00003392335,0.00003057812,0.002781468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1347772,"threshold_uncertainty_score":0.6406475,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0179659904279273,"score_gpt":0.294829534070764,"score_spread":0.2768635436428367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}